Helius Medical Technologies Inc. (NASDAQ:HSDT) marked $0.64 per share on Tuesday, down from a previous closing price of $0.74. While Helius Medical Technologies Inc. has underperformed by -12.98%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, HSDT fell by -95.82%, with highs and lows ranging from $16.22 to $0.65, whereas the simple moving average fell by -85.68% in the last 200 days.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
On March 24, 2021, Noble Capital Markets started tracking Helius Medical Technologies Inc. (NASDAQ: HSDT) recommending Outperform.
Analysis of Helius Medical Technologies Inc. (HSDT)
Further, the quarter-over-quarter increase in sales is 50.00%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Helius Medical Technologies Inc.’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -181.20% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.60, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.07M can be a very valuable indicator of volatility for HSDT stock. On a monthly basis, the volatility of the stock is set at 14.71%, whereas on a weekly basis, it is put at 16.65%, with a loss of -43.01% over the past seven days. Furthermore, long-term investors anticipate a median target price of $25.00, showing growth from the present price of $0.64, which can serve as yet another indication of whether HSDT is worth investing in or should be passed over.
How Do You Analyze Helius Medical Technologies Inc. Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.10%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 28.20% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in HSDT shares?
The recent increase in stakes in HSDT appears to be a result of several institutional investors and hedge funds increasing their positions. Columbus Capital Management LLC’s position in HSDT has increased by 90.09% in the first quarter. The company now owns 278,010 shares of the stock, with a value of $0.33 million, following the purchase of 131,760 additional shares during the last quarter. AIGH Capital Management LLC made another increased to its shares in HSDT during the first quarter, upping its stake by 2.16%. During the last quarter, the company dropped down 5,400 additional shares for a total stake of worth $0.3 million, bringing number of shares owned by the company to 255,400.
During the first quarter, Kepos Capital LP subtracted a -25,304 position in HSDT. Worth Venture Partners LLC purchased an additional 5400.0 shares in the last quarter, increasing its holdings by 9.42%, now holding 62750.0 shares worth $74045.0. At the end of the first quarter, The Vanguard Group, Inc. decreased its HSDT holdings by -31.60% and now holds 53886.0 HSDT shares valued at $63585.0 with the lessened 24894.0 shares during the period. HSDT shares are owned by institutional investors to the tune of 28.20% at present.